Trading Signals: INSM Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Insmed Inc)
| INSM latest price $20.3500 (-10.23%) ($19.8500 - $23.0800) on Fri. Sep. 25, 2015. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 3.92% (three month average) | | RSI | 34 | | Latest Price | $20.3500(-10.23%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | INSM declines -4.5% a day on average for past five trading days. | | Weekly Trend | INSM declines -3.7% a week on average for past two weeks. | | Market Behavior | Growth stock sell-off for large cap. Value stock sell-off for small cap. | | Correlated ETFs | Broad market will support INSM advance at 0% a week (0% probability)
XBI(50%) IBB(48%) IWO(44%) ARKG(42%) IWM(40%) | | Factors Impacting INSM price | INSM will decline at least -1.96% in a week (0% probabilities).
VIXM(-15%) TLT(-9%) SHY(-5%) UUP(-4%) IGOV(-2%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.96% (StdDev 3.92%) | | Hourly BBV | 0 () | | Intraday Trend | -11.8% | | | | | |
|
| 1 - 5 Day Possible Target | $13.7(-32.68%) | | Resistance Level | $24.45 | | 5 Day Moving Average | $23.09(-11.87%) | | 10 Day Moving Average | $24.22(-15.98%) | | 20 Day Moving Average | $24.45(-16.77%) | | To recent high | -25.8% | | To recent low | 0% | | Market Cap | $2.064b | | | | | | |
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ. |